HLC-001
Non-infectious pulmonary complications after hematopoietic stem cell transplantation (NIPCs)
Phase 3In progress
Key Facts
Indication
Non-infectious pulmonary complications after hematopoietic stem cell transplantation (NIPCs)
Phase
Phase 3
Status
In progress
About Human Life CORD
Japanese biotech developing umbilical cord-derived mesenchymal stromal cell therapies for inflammatory and respiratory diseases.
View full company profileAbout Human Life CORD
Japanese biotech developing umbilical cord-derived mesenchymal stromal cell therapies for inflammatory and respiratory diseases.
View full company profileAbout Human Life CORD
Japanese biotech developing umbilical cord-derived mesenchymal stromal cell therapies for inflammatory and respiratory diseases.
View full company profileAbout Human Life CORD
Japanese biotech developing umbilical cord-derived mesenchymal stromal cell therapies for inflammatory and respiratory diseases.
View full company profile